This clinical trial is focused on patients with certain types of cancer, including BRCA Mutated Ovarian Cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, gBRCA mutated metastatic pancreatic cancer, prostate cancer, and endometrium cancer. The study involves a medication called Olaparib, which is available in the form of film-coated tablets. Olaparib is a chemical substance used to treat these cancers, and it is also known by its code name, AZD2281.
The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Olaparib and are still benefiting from it. The study aims to ensure the safety and tolerability of the ongoing treatment. Patients will continue to receive Olaparib if they are judged by their doctor to be benefiting from the treatment. The study will monitor the patients’ health and any side effects that may occur during the treatment period.
Participants in this study will take Olaparib tablets orally, with the treatment period lasting up to 123 days. The study will keep track of any serious side effects or important medical events that happen up to 30 days after the last dose of the study drug. This trial is designed to help patients who are already experiencing positive effects from Olaparib to continue their treatment safely.



Belgium
Bulgaria
Czechia
France
Germany
Hungary
Italy
Poland
Portugal
Slovenia
Spain
Sweden